Скачать или смотреть Discussing eye care while on a targeted treatment | See abbv.ie/ElaherePI

Please see https://www.abbv.ie/ElaherePI for full Prescribing Information, including BOXED WARNING.

Watch as Megan Lanigan, a certified registered nurse practitioner specializing in gynecologic oncology, provides valuable insights on how to talk to patients about eye care after being prescribed ELAHERE, including potential ocular adverse reactions, pointers on finding an eye doctor, and helpful tips for administering eye drops.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

● ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis.
● Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated.
● Administer prophylactic artificial tears and ophthalmic topical steroids.
● Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose.
● Discontinue ELAHERE for Grade 4 ocular toxicities.

Please see additional Important Safety Information at https://www.ELAHEREhcp.com/#isi.

Learn more at https://www.ELAHEREhcp.com.

© 2025 AbbVie. All rights reserved.
ELAHERE® and its design are trademarks of ImmunoGen, Inc., an AbbVie company.
US-EPROC-250679

#ELAHERE #PatientCommunication #OvarianCancer #GynecologicOncology #NursePractitioner